Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSP3-LSP
- Development stage
- Phase 2
- Lead developer
- Vac4All
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Subcutaneous
01
Overview
MSP3-LSP (Merozoite Surface Protein 3 Long Synthetic Peptide) is a blood-stage malaria vaccine candidate developed by the Institut Pasteur and the Vac4All initiative. It consists of a 96-amino-acid long synthetic peptide corresponding to a highly conserved C-terminal region (amino acids 181 to 276) of the Plasmodium falciparum merozoite surface protein 3 (MSP3). The vaccine is designed to induce cytophilic antibodies (primarily IgG1 and IgG3) that cooperate with blood monocytes to inhibit parasite growth through antibody-dependent cellular inhibition (ADCI). MSP3-LSP has been evaluated in Phase I and Phase IIb clinical trials in malaria-endemic regions, formulated with adjuvants such as aluminum hydroxide (Alhydrogel) or Montanide ISA 720.
- Other names
- MP3-LSPMP-3-LSPMP 3-LSPMSP3 long synthetic peptideMSP-3 long synthetic peptideMSP 3 long synthetic peptideMSP3-1 LSPMSP-3-1 LSPMSP 3-1 LSPMSP3-LSP/AlOHMSP3-LSP/Alum
02
Targets
FCGR2A (Low affinity immunoglobulin gamma Fc receptor II-a)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)MSP1 (Merozoite surface protein 1)MSP3 (Plasmodium falciparum merozoite surface protein 3)
Beyond the preview
Go deeper on MSP3-LSP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSP3-LSP.